Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, <i>in-vitro</i> and <i>in vivo</i> study

Luo, Qing; Yang, Jingjing; Xu, Hao; Shi, Jieran; Liang, Zhen; Zhang, Rui; Lü, Ping; Pu, Guojuan; Zhao, Na; Zhang, Junjie

doi:10.1080/10717544.2022.2048134

Cited by 22 publications

(13 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several relevant recent studies (ref. [36][37][38][39][40][41][42][43][44][45][46][47] reporting typical values of a are as follows.…”

Section: Related Experimental Resultsmentioning

confidence: 99%

“…In agreement with the previous studies reviewed by Mircioiu et al, 7 recent studies (ref. [36][37][38][39][40][41][42][43][44][45][46][47] focused on various cargos and carriers show that a is often in the range from 0.45 to 0.85. As I have illustrated in Section III, the Weibull and Korsemeyer-Peppas expressions with this range of a can easily be reproduced by using the model under consideration with appreciable heterogeneity.…”

Section: Related Experimental Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Release of molecules from nanocarriers

Zhdanov

2023

Phys. Chem. Chem. Phys.

View full text Add to dashboard Cite

show abstract

“…Several relevant recent studies (ref. [36][37][38][39][40][41][42][43][44][45][46][47] reporting typical values of a are as follows.…”

Section: Related Experimental Resultsmentioning

confidence: 99%

Section: Related Experimental Resultsmentioning

confidence: 99%

Release of molecules from nanocarriers

Zhdanov

2023

Phys. Chem. Chem. Phys.

View full text Add to dashboard Cite

show abstract

“… [ 304 ] NLC Monolaurin, Monostearin, Glyceryl tripalmitate, Palmitin Glyceryl stearate Sorafenib Demonstrated excellent physicochemical properties and good tolerance, sustained release, and enhanced ocular bioavailability in CNV after topical administration. [ 305 ] NLC Glyceryl monostearate, lipoplysaccharides Dasatinib Observed sustained release, reduced ocular toxicity, and facilitated penetration into cornea via topical administration with effective inhibition of CNV. [ 306 ] Dendrimer Lecithin Anti-VEGF Plus Oligonucleotide 1 Topical delivery of dendrimers plus ODN-1 to the eyes of rats and inhibited laser-induced CNV for up to 6 months.…”

Section: Formulation Approachesmentioning

confidence: 99%

Ocular Delivery of Therapeutic Proteins: A Review

2023

View full text Add to dashboard Cite

Therapeutic proteins, including monoclonal antibodies, single chain variable fragment (ScFv), crystallizable fragment (Fc), and fragment antigen binding (Fab), have accounted for one-third of all drugs on the world market. In particular, these medicines have been widely used in ocular therapies in the treatment of various diseases, such as age-related macular degeneration, corneal neovascularization, diabetic retinopathy, and retinal vein occlusion. However, the formulation of these biomacromolecules is challenging due to their high molecular weight, complex structure, instability, short half-life, enzymatic degradation, and immunogenicity, which leads to the failure of therapies. Various efforts have been made to overcome the ocular barriers, providing effective delivery of therapeutic proteins, such as altering the protein structure or including it in new delivery systems. These strategies are not only cost-effective and beneficial to patients but have also been shown to allow for fewer drug side effects. In this review, we discuss several factors that affect the design of formulations and the delivery of therapeutic proteins to ocular tissues, such as the use of injectable micro/nanocarriers, hydrogels, implants, iontophoresis, cell-based therapy, and combination techniques. In addition, other approaches are briefly discussed, related to the structural modification of these proteins, improving their bioavailability in the posterior segments of the eye without affecting their stability. Future research should be conducted toward the development of more effective, stable, noninvasive, and cost-effective formulations for the ocular delivery of therapeutic proteins. In addition, more insights into preclinical to clinical translation are needed.

show abstract

“…In vitro drug release tests can be carried out with the use of dialysis tubes and Franz diffusion cells [175]. These experiments are usually carried out in either artificial tear fluid or normal PBS solution with membranes and a dialysis bag made out of cellophane or some cellulose derivative with a molecular weight cut off around 10 kD [176][177][178][179].…”

Section: In Vitromentioning

confidence: 99%

Recent Options and Techniques to Assess Improved Bioavailability: In Vitro and Ex Vivo Methods

et al. 2023

View full text Add to dashboard Cite

Bioavailability assessment in the development phase of a drug product is vital to reveal the disadvantageous properties of the substance and the possible technological interventions. However, in vivo pharmacokinetic studies provide strong evidence for drug approval applications. Human and animal studies must be designed on the basis of preliminary biorelevant experiments in vitro and ex vivo. In this article, the authors have reviewed the recent methods and techniques from the last decade that are in use for assessing the bioavailability of drug molecules and the effects of technological modifications and drug delivery systems. Four main administration routes were selected: oral, transdermal, ocular, and nasal or inhalation. Three levels of methodologies were screened for each category: in vitro techniques with artificial membranes; cell culture, including monocultures and co-cultures; and finally, experiments where tissue or organ samples were used. Reproducibility, predictability, and level of acceptance by the regulatory organizations are summarized for the readers.

show abstract

Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study

Cited by 22 publications

References 82 publications

Release of molecules from nanocarriers

Release of molecules from nanocarriers

Ocular Delivery of Therapeutic Proteins: A Review

Recent Options and Techniques to Assess Improved Bioavailability: In Vitro and Ex Vivo Methods

Contact Info

Product

Resources

About